FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
l	OMB Number:	3235-0287									
	Estimated average burde	en									
l	hours per response:	0.5									

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					0.	. 000.	000()	or tire	IIIVESIIIEIII	•		. 10 .0								
1. Name ar					ker or Tradir				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)											
CONRAD HERBERT J							Celldex Therapeutics, Inc. [ CLDX ]								r		10% Ov	vner		
(Last) (First) (Middle) C/O CELLDEX THERAPEUTICS, INC.							of Earliest 017	Trans	saction (Mor	nth/D	ay/Year)					Other (s below)	specify			
	NTAGE RO				$\vdash$															
							4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) HAMPTON NJ 08827											)	X Form filed by One Reporting Person  Form filed by More than One Reporting  Person								
(City)	(S	tate)	(Zip)																	
		Tal	ble I - Nor	n-Deri	vativ	e Se	curitie	s Ac	quired, [	Disp	oosed o	f, or Ber	neficially	y Owned						
1. Title of Security (Instr. 3)  2. Transposite (Month/L						2A. Deemed Execution Date, if any (Month/Day/Yea			e, Transaction Dispose Code (Instr. 5)		Disposed	ties Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amour Securitie Beneficia Owned F Reported	es Form ally (D) o following (I) (II		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	٧	Amount	(A) or (D)	Price	Transact	nsaction(s) tr. 3 and 4)			(311 4)		
Common Stock, par value \$0.001 per share 06/15.							/2017		A		10,000	000 A		38,	38,500		D			
			Table II -						uired, Di s, options		,		,	Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisabl Expiration Date (Month/Day/Year)			of Securities		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
					Code	v	(A) (D		Date Exercisable		Expiration Date	Title	Amount or Number of Shares							
Non- Qualified Stock Option (right to	\$2.32	06/15/2017			A		15,000		06/15/2018 <sup>()</sup>	(3)	06/15/2027	Common Stock	15,000	\$0	15,00	0	D			

## Explanation of Responses:

- 1. On June 15, 2017, the Company awarded 10,000 shares of Company common stock as an annual equity grant in the form of restricted stock awards under the Celldex Therapeutics, Inc. 2008 Stock Option Plan subject to time-based forfeiture restrictions.
- $2. \ Represents option \ granted \ by \ the \ Issuer \ pursuant \ to \ its \ 2008 \ Stock \ Option \ and \ Incentive \ Plan.$
- 3. Such option vests in three equal annual installments beginning June 15, 2018.

/s/ Avery W. Catlin, attorney in fact for Herbert J. Conrad 06/16/2017

\*\* Signature of Reporting Person D

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.